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Objectives The objective of this study was to
quantify the cost burden of unintended
pregnancies (UPs) in Norway, and to estimate the
proportion of costs due to imperfect contraceptive
adherence. Potential cost savings that could arise
from increased uptake of long-acting reversible
contraception (LARC) were also investigated.
Methods An economic model was constructed to
estimate the total number of UPs and associated
costs in women aged 15–24 years. Adherence-
related UP was estimated using ‘perfect use’ and
‘typical use’ contraceptive failure rates. Potential
savings from increased use of LARC were projected
by comparing current costs to projected costs
following a 5% increase in LARC uptake.
Results Total costs from UP in women aged
15–24 years were estimated to be 164 million
Norwegian Kroner (NOK), of which 81.7% were
projected to be due to imperfect contraceptive
adherence. A 5% increase in LARC uptake was
estimated to generate cost savings of NOK 7.2
million in this group.
Conclusions The cost of UP in Norway is
substantial, with a large proportion of this cost
arising from imperfect contraceptive adherence.
Increased LARC uptake may reduce the UP
incidence and generate cost savings for both the
health care payer and contraceptive user.
INTRODUCTION
Despite the wide availability of contra-
ception in Norway, there is evidence to
suggest high numbers of unintended
pregnancies (UPs). Rates of abortion, one
of the indicators of UP, are high in young
women, with observed rates rising from
26.3 to 27.6 per 1000 women aged
15–24 years between 2001 and 2011.1
UP has been declared a public health
issue in Norway by the Norwegian
Directorate of Health in the ‘Action Plan
for the Prevention of Unintended
Pregnancies and Abortions 2010–2015’,2
and is likely to be associated with sub-
stantial health system costs. In general,
contraceptive costs are borne
out-of-pocket by contraceptive users. For
women aged 16–19 years, oral contracep-
tives (OCs), patch and ring are reim-
bursed up to Norwegian Kroner (NOK)
416 (€50.7) per year. (NB. Conversion
rates September 2014: £1=NOK 10.4;
1€=NOK 8.2).
Available methods of contraception are
effective when used correctly (‘perfect
use’); however, in practice incorrect and
inconsistent method use (‘typical use’)
results in diminished real-world effective-
ness.3 Short-acting reversible contraception
(SARC; comprising oral contraception,
injection, ring and patch) is more reliant
on user adherence, and thus has high
typical use failure rates when compared
to long-acting reversible contraception
[LARC; comprising the implant, copper
intrauterine device (IUD) and hormonal
Key message points
▸ Unintended pregnancy (UP) in Norway
generates substantial costs to the
health care payer.
▸ A large proportion of UPs is estimated
to be attributable to imperfect contra-
ceptive adherence, particularly amongst
younger women who have high uptake
of short-acting reversible contraception.
▸ Increased long-acting reversible contra-
ception uptake may reduce the inci-
dence of UP and generate cost savings
for both the health care payer and
contraceptive user.
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intrauterine system (IUS)]. [NB. Besides SARC and
LARC methods, the analysis included barrier methods
(using male condom as a proxy), withdrawal, calendar
methods, and no method (chance)]. A previous study
from a USA perspective indicated that rates of
adherence-related UP were high in current practice and
that shifting usage towards increased LARC uptake may
result in reduced rates of UP and associated costs.4
In Norway, uptake of SARC or barrier methods is
high in young women5 and may contribute to substan-
tial numbers of potentially avoidable adherence-related
UP. To date, there is no study quantifying the costs of UP
and proportion due to imperfect contraceptive adher-
ence in Norway. The current study reports the number
and cost of UP outcomes estimated over a 1-year period
in Norway, and explores potential cost savings that
could be generated through increased LARC uptake.
METHODS
Model structure
A previous study4 was used as the framework for the
current analysis. A cost of UP model was constructed
to estimate the number and costs of UP over an
average 1-year period. The proportion of UP attribut-
able to imperfect adherence and projected cost savings
from a switch in contraceptive usage from SARC to
LARC were also explored. Analyses were conducted
from the societal perspective, accounting for direct
and indirect costs incurred by both the health care
payer and women using contraception. The analysis
was limited to consideration of the costs of UP events
only; longer term social and economic consequences
of UP were not considered in the model.
Population
The model considered women aged 15–44 years
requiring reversible contraception and at risk of preg-
nancy, divided into 5-year age groups to capture dif-
ferences in pregnancy outcomes and contraceptive
method use. Base case analyses were conducted in
women aged 15–24 years, as this cohort represents a
key target group for increased LARC uptake due to
high current utilisation of SARC.5 This age group is
also the focus of policy efforts in Norway to curb
rates of UP and particularly abortions through use of
more effective contraceptive methods.2
Number of UP events
To determine the number of UP events over an
average 1-year period, four possible pregnancy out-
comes were considered in the model: live birth,
induced abortion, spontaneous abortion, and ectopic
pregnancy, with the probability of outcome differen-
tiated by age category. The annual number of live
births was retrieved from national statistics data, as
was the number of induced abortions.6 7 The number
of spontaneous abortions was not reported directly in
the literature; data on the incidence of spontaneous
abortions in relation to induced abortions8 were used
to calculate a ratio between the two, which was
applied to the number of induced abortions to esti-
mate the number of spontaneous abortions. The total
number of ectopic pregnancies was obtained from
diagnosis-related groups (DRG) case data9; age strati-
fied figures were not available, hence USA data10 11
were used to determine the relative distribution of
ectopic pregnancy events across age groups, and so
estimate the number of events by age category.
To translate all pregnancy outcomes into estimates
of UP only, proportions of ’unintendedness’ were
applied to the data. For live birth and induced abor-
tion these were obtained from an unpublished study
by FE Skjeldestad (co-author; see Table 1), whilst pro-
portions for spontaneous abortion and ectopic preg-
nancy were assumed with clinician input to be 0.5 for
all age groups in the absence of available study data.
The product of these and pregnancy events generated
estimates of total UP outcomes. UP numbers were esti-
mated for each 5-year age band included within the
15–44 years category.
Costs of UP-related events
Costs associated with UP outcomes were derived using
2012 costs from the Norwegian Directorate of
Health.9 12 Weighted average costs of pregnancy out-
comes were estimated by multiplying the proportions
of DRG-coded events occurring within each preg-
nancy outcome class by the corresponding DRG costs.
For live births, a further summary weighted cost was
calculated using the costs and relative incidence of
vaginal versus caesarean deliveries. Calculated preg-
nancy outcome costs are presented in Table 2. Total
UP costs were estimated by multiplying the numbers
of each UP outcome by the corresponding outcome
costs. The proportion of unintended births that were
mistimed (versus unwanted) were adjusted for in scen-
ario analyses by re-weighting the cost of a live birth,
following a previously published methodology.13
Proportion of UPs due to imperfect contraceptive
adherence
Contraceptive methods are associated with both
‘perfect use’ failure rates under trial conditions, and
Table 1 Proportions of unintendedness of live birth and induced
abortion, by age group
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‘typical use’ rates, reflecting contraceptive effective-
ness in a real-world setting. The model included 11
reversible methods of contraception, comprising
LARC (IUS, IUD, implant), SARC (OC, ring, patch,
injection), barrier methods, calendar method, with-
drawal, and no method (chance). The difference
between perfect and typical use failure rates was
assumed to be an appropriate proxy for imperfect
adherence. The proportion of failures attributable to
imperfect adherence was subsequently calculated for
each method included in the analysis (Table 3).
To estimate the total proportion of UPs resulting
from imperfect adherence, firstly contraceptive uptake
distributions amongst all women in the included
population were derived using data from the literature
and the Norwegian Prescription Database.5 15
Reported distributions of use were re-weighted to
account for reversible methods only. The proportion
of women expected to incur a UP was then deter-
mined by multiplying method uptake percentages by
typical use method failure probabilities. To determine
the probability of an adherence-related UP, these were
further multiplied by the method-specific probabilities
of UP due to imperfect adherence.
Dividing the total proportion of women expected
to have an adherence-related UP by the total propor-
tion of women expected to have any UP generated an
estimate of the overall proportion of UP predicted to
result from imperfect adherence. This proportion was
multiplied by total UP costs to determine the contri-
bution from imperfect adherence.
Cost of contraception
The number of women using each of the contracep-
tive methods considered in the model was determined
by first establishing the total number of women in the
Norwegian population for each of the included age
groups.16 Only women at risk of pregnancy and using
reversible contraception were eligible for inclusion in
the model; to refine the model population to include
only this group, the proportion considered not at risk
was removed (i.e. women who were pregnant, post-
partum, seeking pregnancy, sterilised, no intercourse),
using a combination of USA and Norwegian data.5 17
The resulting population was then multiplied by the
contraceptive uptake distribution to allocate patients
across each contraceptive method.
Ingredient costs for each contraceptive method
included in the model were retrieved from electronic
databases18 19 (Bayer, data on file). The number of
units of each contraceptive method required in a year
was assumed using Summary of Product
Characteristics information and the literature.20
Contraceptive medical consultations were also cap-
tured. It was assumed that all LARC methods were
associated with an insertion consultation, one
follow-up consultation, and a removal consultation.
For SARC (excluding injection) it was assumed that in
an average year of use there was half a consultation,
representing a consultation visit on average every
other year. In line with standard practice in Norway,
this assumes that a general practitioner (GP) consult-
ation is not required for every refill prescription.
Injection was assumed to be associated with four
administration consultations per year, one of which
was assumed to also encompass product prescription.
Device fittings and method administration for LARC
were assumed to be performed by a GP, gynaecologist
or nurse. The proportions of IUD/IUS and implant fit-
tings conducted by a GP versus a gynaecologist were
obtained from another unpublished study by FE
Skjeldestad. For injections, an equal split between GP
and nurse administration was assumed due to a lack
of published evidence, though the proportion of pre-
scriptions prescribed, stratified by health care practi-
tioner, was obtained from the unpublished study by
FE Skjeldestad mentioned earlier.
To permit comparability between contraceptives
with differing durations of use, total contraceptive
costs were annualised. For SARC, product ingredient
unit costs and consultation costs were multiplied by
the respective number of each required in a year of
Table 3 Proportions of unintended pregnancy rates attributable














OC 0.0900 0.0030 0.967
Ring 0.0900 0.0030 0.967
Patch 0.0900 0.0030 0.967
Injection 0.0600 0.0020 0.967
Implant 0.0005 0.0005 0.000
IUD 0.0080 0.0060 0.250
IUS 0.0020 0.0020 0.000
Barrier methods* 0.1800 0.0200 0.889







*Data for male condom used as a proxy for barrier methods.
†Ovulation method used as a proxy for calendar methods.
IUD, intrauterine device; IUS, intrauterine system; NA, not applicable;
OC, oral contraceptive; UP, unintended pregnancy.
Table 2 Pregnancy outcome cost, by outcome9 12
Pregnancy outcome Weighted average cost (NOK)
Live birth 23 354.69
Induced abortion 4892.21
Spontaneous abortion 7507.97
Ectopic pregnancy 33 874.50
NOK, Norwegian Kroner.
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product use. For LARC, the costs of a single product
unit and total number of consultations incurred over
the product lifetime were divided by the respective
durations of product use. Total costs for each method
and annualisation factors are presented in Table 4.
Total contraceptive costs at the population level were
estimated as the product of the number of women
using each method and the corresponding costs.
Indirect costs
Indirect costs were limited to consideration of days lost
from work. For each possible UP outcome, a duration
of time lost from work was assumed in conjunction
with clinician input. Live birth was expected to fall
under maternity leave and therefore was not included.
Induced abortion, spontaneous abortion and ectopic
pregnancy were assumed to be associated with three,
two and four work days lost, respectively.
Contraceptive consultations for insertion, removal and
follow-up, respectively, were each assumed to elicit
0.25 days of lost work time. The assumed duration of
time lost for each UP outcome and contraceptive con-
sultation was multiplied by age-specific weighted mean
daily earnings for women in Norway, calculated using
data from Statistics Norway.21 Women aged 15–19
years were not included in the indirect cost calculation;
it was assumed that the majority of women within this
age group would not be in paid employment.
Cost savings from a switch from SARC to LARC
To explore the impact of increased LARC uptake, 5%
of women aged 15–24 years using SARC methods in
the model were allocated to LARC. SARC users were
redistributed in proportion to baseline uptake of
included LARC methods. The proportion of women
expected to incur a UP under current contraceptive
utilisation was calculated by multiplying contraceptive
uptake distributions by the corresponding failure rates
for each method. This was compared to the projected
proportion of women estimated to incur a UP assum-
ing a 5% switch, and the percentage change in pre-
dicted UP incidence.
The calculated percentage reduction in UPs follow-
ing the 5% switch to LARC was multiplied by the
base case estimate of total UP costs to determine pos-
sible UP-related cost savings. The cost impact of the
modified contraceptive utilisation was also considered
by comparing total contraceptive costs before and
after the switch. One-way sensitivity analysis (OWSA)
was conducted to evaluate the robustness of projected
cost savings to a standard 30% variation in the value
of parameters likely to be key model drivers, including
population, efficacy, medical cost and resource use
parameters. An exploratory analysis modelled the
potential impact of all women aged 15–24 years using
SARC switching to LARC.
Scenario analyses exploring the impact of lower
typical use method failure rates, using non-annualised
costs, and a break-even analysis were also undertaken
(see online Supplementary Material for full method-
ology details).
RESULTS
Number and cost of UPs
In the target age group of women aged 15–24 years, a
total of 11 443 UPs were estimated, generating total
costs of NOK 144 million (€18.0 million),22 of which
NOK 133 million (€16.5 million) were direct and
NOK 11.6 million (€1.5 million) were indirect costs.
In the broader 15–44 years age group, 39 131 UPs
and associated costs of NOK 617 million (€77.1
million) were estimated, of which NOK 568 million
(€70.8 million) were direct and NOK 49.8 million
(€6.2 million) were indirect costs. Total costs by age
group are presented in Table 5. Applying an adjust-
ment factor to account for the proportion of births
that were mistimed rather than unwanted, total costs
of UP amounted to NOK 72 million (€9.0 million) in
women aged 15–24 years, and to NOK 346 million
(€43.2 million) in women aged 15–44 years.
Proportion of UPs due to imperfect adherence
Imperfect adherence was estimated to account for
81.7% of UPs in the 15–24 years age group, the
largest proportion amongst all age groups considered
in the model (Figure 1). The cost contribution of
adherence-related UP in this group was estimated to
be NOK 118 million (€14.7 million) (Table 5). The
proportion of UPs attributable to imperfect adherence
in the 15–44 years group was estimated to be 60.4%,
pertaining to costs of NOK 398 million (€49.7
million).












IUS 1711.20 0.20 342.24
Implant 1667.00 0.33 555.67
IUD 791.80 0.20 158.36
Injection 841.69 1.00 841.69
OC 737.01 1.00 737.01
Ring 1509.32 1.00 1509.32
Patch 1215.63 1.00 1215.63
Barrier methods* 98.22 1.00 98.22
Withdrawal 0.00 1.00 0.00




*Data for male condom used as a proxy for barrier methods.
†Ovulation method used as a proxy for calendar methods.
IUD, intrauterine device; IUS, intrauterine system; NOK, Norwegian Kroner;
OC, oral contraceptive.
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Cost of contraception
The estimated cost of contraception in the 15–24
years group was NOK 135 million (€16.8 million),
and NOK 437 million (€54.6 million) in the 15–44
years group. Accounting for both the cost of UP and
contraceptive use, total average annual costs incurred
in Norway are projected to amount to NOK 279
million (€34.8 million) for women aged 15–24 years,
of which NOK 254 million (€31.6 million) were
direct costs and NOK 25 million (€3.1 million) were
indirect costs. Of the direct costs, NOK 154 million
(€19.2 million) were borne by the public health care
payer and NOK 100 million (€12.4 million) by
out-of-pocket payments by contraceptive users. Total
average annual costs in all women aged 15–44 years
amounted to NOK 1.06 billion (€131.6 million), of
which direct costs were NOK 899 million (€112.2
million) and indirect costs were NOK 156 million
(€19.5 million). Of the direct costs, NOK 589 million
(€73.5 million) were borne by the public health care
payer and NOK 316 million (€39.4 million) by
out-of-pocket payments by contraceptive users.
Impact of a switch from SARC to LARC methods
A 5% switch from SARC to LARC yielded expected
cost savings of NOK 6.5 million (€815 000) in the
15–24 years age group, a 2.34% reduction in costs.
OWSA indicated that cost savings were maintained
across all parameter values tested (Figure 2).
Increasing the proportion of women switching from
SARC to LARC to 10% generated projected cost
savings of NOK 13 million (€1.6 million), whilst a
hypothetical scenario in which all women switched
from SARC to LARC generated projected costs
savings of NOK 131 million (€16.3 million), repre-
senting a 47% reduction in costs.
Reduced typical use failure rates
A scenario analysis exploring the impact of typical use
method failure rates lowered by 30% revealed cost
savings of NOK 6.3 million (€787 000) following a
5% switch from SARC to LARC in women aged
15–24 years, equivalent to a reduction of 2.26%. The
total cost of UP due to imperfect adherence was esti-
mated to be NOK 108 million (€13.5 million).
Non-annualised costs and break-even analysis
Using non-annualised LARC costs resulted in a pro-
jected cost increase of NOK 9.9 million (€1.2 million)
in women aged 15–24 years following a 5% switch
from SARC to LARC. Cost neutrality analysis indi-
cated that LARC use was required for 1.28 years to
generate a net cost impact of zero.
DISCUSSION
This study demonstrates that UP represents a substan-
tial economic burden in Norway, contributing to total
costs of NOK 617 million (€77.1 million) in women
aged 15–44 years, and NOK 144 million (€18.0
million) in women aged 15–24 years. Approximately
Table 5 Total unintended pregnancy costs and proportion due








15–19 2781 23 680 252 19 381 784
20–24 8661 120 558 228 98 367 407
25–29 8900 142 000 485 97 198 418
30–34 9497 170 879 370 103 705 521
35–39 7216 128 949 385 70 544 967
40–44 2075 31 686 025 8 822 814
15–44 39 131 617 753 745 398 020 911
15–24 11 443 144 238 480 117 749 191
NOK, Norwegian Kroner; UP, unintended pregnancy.
Figure 1 Proportions of unintended pregnancies attributable to imperfect adherence, by age group.
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10% of these costs were indirect, demonstrating the
extent of potential productivity loss associated with
UP. Our results further indicate that a large proportion
of total costs is attributable to imperfect adherence,
and thus potentially avoidable. Of all women evalu-
ated in the model, the largest proportion of UP attrib-
utable to imperfect adherence was estimated to be in
the target group of women aged 15–24 years. In line
with this finding, our analysis suggests that a 5%
switch from SARC to LARC in women aged 15–24
years yields a substantial reduction in costs associated
with UP outcomes, generating savings of NOK 6.5
million (€815 000). Whilst the majority of direct costs
(63%) were projected to be borne by the public health
care payer, a substantial proportion (37%) was pro-
jected to be incurred out-of-pocket by the contracep-
tive user due to contraceptive product costs. Cost
savings through increased LARC uptake are thus likely
to reduce the cost burden faced by both women and
the national health care payer.
Despite higher upfront costs, cost neutrality analysis
indicated that LARC methods on average require use
for 1.28 years before cost savings are generated fol-
lowing a switch from SARC to LARC. Given that
LARC methods have a minimum of 3-year duration of
product efficacy, it is reasonable to assume that poten-
tial cost savings from increased LARC uptake would
be realised.
In Norway, LARC usage rates among young women
remain low despite a recent increase in uptake of
LARC methods in all women requiring contraception
in Norway.2 An experimental scheme investigated the
impact of expanding current regulation and offering
free contraception including LARC to women aged
20–24 years. It observed a significant increase in
uptake of hormonal contraception in general and
LARC methods in particular, as well as a significant
decline in the incidence of abortions in the interven-
tion population.23 Further promoting LARC uptake in
younger women may help to realise the cost savings
from both UP and contraceptive use predicted in our
model.
There are a number of limitations to the analysis.
USA data were used to calculate the proportion of
women at risk of pregnancy, given a lack of data spe-
cific to Norway. Similarly, contraceptive failure rates
used in the model were taken from studies in the
USA. As typical failure rates have been shown to be
higher in the USA compared to European popula-
tions,24 the proportion of UP attributable to imperfect
adherence may have been overestimated. Nonetheless,
scenario analyses using reduced method failure rates
continued to generate substantial cost savings follow-
ing a switch. Only first-year contraceptive failure rates
were available, which may be higher than in subse-
quent years of use. Consequently, the estimated
number of UP as well as cost savings generated from
switching to LARC methods may be overstated.
Only costs of pregnancy outcome events were
included in the model; prenatal costs and other social/
economic costs of UP were not modelled.
Additionally, side effects and the impact of contracep-
tive discontinuation and switching were not consid-
ered in the model and warrant additional research. In
the absence of published evidence, clinician input was
used to estimate the proportion of spontaneous abor-
tions and ectopic pregnancies that were unintended.
Exclusion of the 15–19 years age group when calcu-
lating indirect costs may have resulted in a slight
underestimate of the true cost burden, given that a
Figure 2 One-way sensitivity analysis results for cost savings post-5% switch from short-acting reversible contraception to
long-acting reversible contraception. NOK, Norwegian Kroner; OC, oral contraceptive.
Article
6 Henry N, et al. J Fam Plann Reprod Health Care 2014;0:1–7. doi:10.1136/jfprhc-2014-100878
group.bmj.com on December 24, 2014 - Published by http://jfprhc.bmj.com/Downloaded from 
small proportion of women within this age group is
likely to be employed, and thus incur productivity
losses from work days missed. Finally, longer-term
outcomes of pregnancy were not considered for this
study, which focuses solely on short-term costs asso-
ciated with the pregnancy event as well as associated
contraceptive use.
Despite the above limitations, this analysis highlights
the significant economic burden stemming from UP in
Norway, and indicates that a substantial proportion of
these costs are attributable to imperfect adherence. In
women aged 15–24 years, an increase in the uptake of
LARC methods could precipitate cost savings benefit-
ing both the health care payer and contraceptive users.
This provides an economic rationale to support poten-
tial legislation extending reimbursement of all methods
of contraception to young women.
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